The research team, led by Yiyue Xu and corresponding author Linlin Wang, systematically searched three major biomedical databases, PubMed, Embase, and Web of Science, for phase III randomized controlled trials published between January 1, 2015, and August 5, 2026. Their inclusion criteria were deliberately strict: only trials evaluating first-line immune checkpoint inhibitor plus chemotherapy regimens in advanced solid tumors qualified. The effort yielded an extraordinary evidence base of 58 phase III randomized controlled trials encompassing 36,664 patients, with regimens combining chemotherapy with 20 distinct immune checkpoint inhibitors across multiple tumor types. That scale matters, because individual trials typically compare a single immunotherapy against chemotherapy alone within one cancer type, leaving clinicians to guess how, say, a PD-L1 inhibitor used in lung cancer might compare on safety with a CTLA-4 pathway agent deployed elsewhere.

The methodological engine of the study is the network meta-analysis, a statistical framework that allows simultaneous comparison of multiple treatments even when they have never been tested against each other directly. By building a network of evidence connected through common comparators, in this case chemotherapy plus placebo, the researchers could estimate odds ratios with 95 percent credibility intervals for every pairwise comparison in the network. They then applied Bayesian ranking probabilities and calculated the surface under the cumulative ranking curve, known as SUCRA, to produce a league table of regimens ordered by safety. The primary outcome was the occurrence of grade 3 or higher immune-related adverse events, the severe toxicities that arise when unleashed immune systems attack healthy tissue. Secondary safety endpoints included all-grade immune-related adverse events and both severe and all-grade treatment-related adverse events more broadly.

The headline finding concerns adebrelimab, an anti-PD-L1 antibody, which emerged as the most favorably ranked regimen for severe immune-related adverse events. Adebrelimab plus chemotherapy achieved the highest SUCRA value in this domain, at 76.27 percent, indicating the strongest cumulative ranking probability among the 17 immune checkpoint inhibitor and chemotherapy regimens analyzed for this outcome. Notably, its pooled odds ratio against placebo plus chemotherapy was 1.62 with a 95 percent credibility interval of 0.28 to 9.83, an interval that crosses one, meaning the analysis could not statistically distinguish its severe immune toxicity risk from chemotherapy alone. For patients and clinicians weighing the trade-off between efficacy and immune toxicity, that profile represents a meaningful signal, though the wide interval also underscores the statistical uncertainty inherent in even the largest networks.

When the researchers turned to the broader toxicity categories, different agents rose to the top. Avelumab plus chemotherapy ranked highest for both all-grade immune-related adverse events and all-grade treatment-related adverse events, suggesting that while this regimen may produce more frequent lower-grade side effects, its overall tolerability profile compared favorably across the network. Meanwhile, regimens built around durvalumab and penpulimab showed the most favorable safety profiles for grade 3 or higher treatment-related adverse events, the severe toxicities of any cause attributable to treatment. The fact that different drugs top different safety categories is itself an important result: it demonstrates that safety is not a single dimension but a multidimensional profile, and the optimal choice may depend on which toxicity domain matters most for a given patient.

Understanding why these differences exist requires a brief tour of immunopharmacology. Immune checkpoint inhibitors work by blocking inhibitory receptors, such as PD-1, PD-L1, and CTLA-4, that normally restrain T-cell activity. Removing these brakes allows immune cells to attack tumors, but the same mechanism can trigger inflammation in the skin, gut, liver, lungs, and endocrine organs, producing the immune-related adverse events that define this drug class. The degree and character of immune activation vary substantially between molecules, depending on target, binding affinity, antibody engineering, and pharmacokinetics. When combined with cytotoxic chemotherapy, which carries its own burden of myelosuppression, nausea, and neuropathy, the resulting toxicity profile reflects a complex interplay that randomized trials rarely dissect in comparative terms. A network meta-analysis of this scale is precisely the tool needed to bring that hidden structure into view.

The rigor of the underlying evidence was assessed using the Cochrane Risk of Bias 2 tool, the current standard for evaluating randomized trials, which judges bias across domains including the randomization process, deviations from intended interventions, missing outcome data, outcome measurement, and selective reporting. By restricting inclusion to phase III trials, the most definitive study design in oncology, the authors minimized the risk that their rankings reflect artifacts of small or preliminary studies. The Bayesian framework additionally allows uncertainty to propagate through the entire network, so that rankings are expressed as probabilities rather than false certainties. Still, the authors and outside observers alike should note the limitations inherent to any such synthesis: trials enrolled different tumor types, used varying chemotherapy backbones, and applied somewhat heterogeneous toxicity grading, all of which can introduce transitivity assumptions that may not hold perfectly across the network.

The clinical implications are considerable. Immune checkpoint inhibitor plus chemotherapy combinations are now standard first-line therapy for multiple advanced solid tumors, including non-small cell lung cancer, and their use continues to expand. With 20 distinct checkpoint inhibitors now validated in this setting, oncologists face a genuine selection problem, and until now the comparative safety evidence has been fragmented across hundreds of individual trials. Severe immune-related adverse events are not merely statistical inconveniences; they can require high-dose corticosteroids, permanent drug discontinuation, hospitalization, and in rare cases prove fatal. A regimen ranking that identifies adebrelimab, avelumab, durvalumab, and penpulimab as comparatively favorable across different safety domains gives clinicians an evidence-based starting point for individualizing treatment, particularly for patients with preexisting autoimmune disease, organ transplants, or frailty who may tolerate immune toxicity poorly.

The study also carries implications for drug development and health policy. Regulators and guideline committees increasingly demand comparative rather than merely placebo-controlled evidence, and SUCRA-based rankings of this kind can inform which agents deserve prioritization in head-to-head trials, which combinations warrant preferential pricing negotiations, and where post-marketing surveillance should concentrate. The authors report no funding or competing interests, and the analysis was conducted by a radiation oncology department team, reflecting the growing recognition that safety, not only survival, defines the value of modern cancer therapy.

Caveats remain, and the authors are careful not to overstate them away. The credibility interval around adebrelimab’s odds ratio is wide, rankings depend on the set of trials available through August 2026, and the analysis addresses safety rather than efficacy, meaning the safest regimen is not automatically the best one for a given cancer. The article was published as a peer-reviewed, citable version carrying a permanent DOI, subject to further editorial processing. Even so, the work stands as a landmark synthesis: by pooling 58 phase III trials and nearly 37,000 patients into a single coherent network, it converts a decade of scattered toxicity data into an actionable hierarchy, and it signals a maturing of immuno-oncology from the era of proving that these drugs work to the more nuanced task of choosing precisely the right one for each patient.

Subject of Research: Comparative safety of immune checkpoint inhibitor plus chemotherapy first-line regimens for solid tumors

Article Title: Comparative safety of immune checkpoint inhibitor combined with chemotherapy as first-line treatment for solid tumors: a systematic review and network meta–analysis

Article References: Xu, Y., Li, B., Gao, A., Zhao, Q., Yang, L., & Wang, L. (2026). Comparative safety of immune checkpoint inhibitor combined with chemotherapy as first-line treatment for solid tumors: a systematic review and network meta–analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-17007-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17007-w

Keywords: immune checkpoint inhibitors, chemotherapy, network meta-analysis, immune-related adverse events, treatment-related adverse events, solid tumors, phase III trials, adebrelimab, avelumab, durvalumab, penpulimab, drug safety